Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer, announced today that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.
Help employers find you! Check out all the jobs and post your resume.
